1. South Korea Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
HK inno.N Corporation

HK inno.N Corporation

KKRX:195940
34,100.00
KRW
0.00
(0.00%)
3,030.87EPS
13.36P/E
1.15TMarket Cap
Nov 04Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
329,485.95
463,110.04
17,676.4
18,008.14
245,346.1
269,950.6
20,704.28
35,486.51
29,790.28
29,258.27
31,672.3
37,526.38
38,079.73
Basic EPS, GAAP
26,476
36,234.01
1,623.78
1,956.33
23,871
6,608.61
965.13
1,140.31
1,342
1,666
2,174
2,672
3,030.87
Free Cash Flow per Basic Share
61,199.96
66,239.63
1,276.76
2,494.71
3,316.46
27,950.57
-1,414.61
-216.7
1,257.15
1,550.51
-704.29
2,671.2
3,530.55
Dividend per Share
- -
- -
1,243.75
- -
60,499.09
70,299.16
- -
- -
188.27
182.35
199.48
349.99
- -
Book Value per Share
11,767.35
13,313.09
13,733.72
16,191.95
12,960.69
30,804.21
31,905.25
39,819.21
41,095.16
42,486.8
44,171.62
46,890.35
47,677.83
Tangible Book Value per Share
10,237.83
11,824.77
12,233.55
14,708.24
11,618.44
-16,069.33
-14,232.3
1,937.48
2,687.49
4,498.07
6,368.3
9,139.17
10,000.36
Basic Weighted Avg Shares
1
1
29
29
2
2
29
22
28
28
28
28
28
Sales/Revenue/Turnover
329,489
463,114
510,927
520,516
490,700
539,908
598,447
769,786
846,522
828,908
897,142
1,063,151
1,078,609
Operating Margin (%)
11.3
11.57
13.28
15.7
11.53
13.42
14.54
6.54
6.2
7.95
9.83
10.43
11.98
Depreciation Expense
15,619
20,061
18,188
18,947
18,883
28,694
29,931
32,249
34,843
38,766
39,738
45,754
- -
Net Income, GAAP
26,476
36,234
46,935
56,547
47,743
13,217
27,897
24,736
38,134
47,199
61,580
75,700
85,850
Effective Tax Rate (%)
17.98
19.17
18.56
19.53
23.16
56.95
47.46
10.97
- -
- -
14.16
17.11
22.28
Profit Margin (%)
8.04
7.82
9.19
10.86
9.73
2.45
4.66
3.21
4.5
5.69
6.86
7.12
7.96
Working Capital
121,279
167,516
171,539
184,704
160,452
50,251
-79,267
41,173
-23,742
-162,182
-78,497
-106,274
-54,220
LT Debt
99,899
99,917
99,936
59,973
59,985
628,608
534,289
252,372
191,183
37,176
166,350
159,580
166,388
Total Equity
272,102
307,845
317,572
374,415
299,697
712,301
743,230
1,150,954
1,164,221
1,203,646
1,251,377
1,328,399
1,350,708
Return on Invested Capital (%)
- -
10.92
13.18
15.17
10.78
3.4
3.11
2.85
- -
- -
4.51
5.17
5.67
Return on Capital (%)
- -
9.86
11.94
13.71
12.39
3.24
2.76
2.71
- -
- -
4.43
5.01
4.87
Return on Common Equity (%)
- -
12.5
15.01
16.34
14.16
2.61
3.85
2.62
3.29
3.99
5.02
5.87
6.54

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
362,758
336,091
284,014
LT Borrowings
143,861
148,805
148,826
LT Finance Leases
15,719
17,946
17,563
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
28
28
28
Market Capitalization
1,396,664
1,389,581
1,147,361

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
486,307
456,354
439,340
Cash, Cash Equivalents & STI
159,569
129,313
116,453
Accounts Receivable, Net
139,378
142,619
137,491
Inventories
168,137
172,662
173,742
Total Current Liabilities
592,580
550,959
493,560
Payables & Accruals
- -
- -
- -
ST Debt
362,758
336,091
284,014
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.26%
13.9%
6.15%
Free Cash Flow
-102.03%
-310.05%
-479.34%
Net Income, GAAP
19.32%
24%
22.93%
Sales/Revenue/Turnover
9.06%
12.65%
18.5%
Total Cash Common Dividend
- -
- -
75.48%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
212,615
219,285
229,470
235,772
897,142
2025
247,359
263,091
260,822
291,879
1,063,151
2026
258,683
267,225
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
370
615
512
677
2,174
2025
615
425
655.03
976.86
2,672
2026
915.8
483
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
199.48
2025
- -
- -
- -
- -
349.99
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Dal-Won Kwak
Full Time Employees
1,723
Sector
Health services
Industry
Medical/Nursing services
Address
239 Osongsaengmyeong 2-ro Cheongju-si NC South Korea 28158
IPO Date
Aug 9, 2021
Website
inno-n.com
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Mobile-health Network Solutions (NASDAQ:MNDR)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
HK inno.N Corporation engages primarily in the development, manufacture, and sale of prescription drugs, health and beverage products, and beauty products in South Korea and internationally. The company offers prescription drugs including the blockbuster potassium-competitive acid blocker K-CAB (tegoprazan) for gastroesophageal reflux disease, erosive esophagitis, and Helicobacter pylori eradication; biopharmaceuticals such as Epokine (recombinant human erythropoietin) for anemia in hemodialysis patients; antibiotics like Cinezolid (linezolid) for vancomycin-resistant enterococcus faecium infections and Citopcin (ciprofloxacin) for various microbial infections; cardiovascular treatments including Exone (amlodipine plus valsartan) for hypertension and Atomet XR (atorvastatin plus metformin) for type 2 diabetes with hyperlipidemia; oncology drugs such as Calmtop RTU (irinotecan) for colorectal cancer and Carevec (imatinib) for chronic myelogenous leukemia; and intravenous nutrition solutions; alongside active pharmaceutical ingredients. It provides health and beverage products featuring the leading anti-hangover brand Condition, health supplements, ready-to-drink beverages like Oriental Raisin Water (Hutgaesoo), and health functional foods; as well as beauty products under the brands bewants for slow-aging cosmetics, ScalpMed for premium hair care, and KLEDERMA RX. HK inno.N Corporation, founded in 1984 and headquartered in Cheongju-si, South Korea, operates manufacturing facilities in Osong, Eumseong, and Icheon, with exports to Japan, Southeast Asia, Latin America, Europe, and the Middle East; it functions as a subsidiary of Kolmar Korea following its prior operation as CJ HealthCare. Recent developments include the March 2025 acquisition of a 10.61% stake in Japan-based drug discovery firm RaQualia to deepen joint R&D and pursue K-CAB commercialization in Japan; expansion of its licensing and supply agreement with Tabuk Pharmaceuticals in May 2025 for exclusive K-CAB rights across 10 Middle Eastern countries; a partnership with Novacell Technology announced in late 2024 for a next-generation FPR2 agonist immunotherapy targeting inflammatory diseases in ophthalmology, dermatology, and respiratory areas; and a May 2024 licensing deal with Sciwind Biosciences for ecnoglutide injection (XW003), a GLP-1/GIP dual agonist for obesity and diabetes, in South Korea.